drugset / Trial / NCT03022045
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the safety and efficacy of two different dose regimens of risankizumab for Japanese subjects with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
Timeline
- Start
- 2017-01-26
- Primary completion
- 2017-09-17
- Completion
- 2020-11-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risankizumab | Monoclonal antibody | 75 mg | Subcutaneous |
| Subject | Risankizumab | Monoclonal antibody | 150 mg | Subcutaneous |